- Home
- ATYR vs JRS Comparison
ATYR vs JRS Comparison
Compare ATYR & JRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ATYR
- JRS
- Stock Information
- Founded
- ATYR 2005
- JRS 2001
- Country
- ATYR United States
- JRS United States
- Employees
- ATYR N/A
- JRS N/A
- Industry
- ATYR Biotechnology: Biological Products (No Diagnostic Substances)
- JRS Finance/Investors Services
- Sector
- ATYR Health Care
- JRS Finance
- Exchange
- ATYR Nasdaq
- JRS Nasdaq
- Market Cap
- ATYR 228.1M
- JRS 267.5M
- IPO Year
- ATYR 2015
- JRS N/A
- Fundamental
- Price
- ATYR $3.63
- JRS $8.65
- Analyst Decision
- ATYR Strong Buy
- JRS
- Analyst Count
- ATYR 5
- JRS 0
- Target Price
- ATYR $19.25
- JRS N/A
- AVG Volume (30 Days)
- ATYR 960.8K
- JRS 86.6K
- Earning Date
- ATYR 03-13-2025
- JRS 01-01-0001
- Dividend Yield
- ATYR N/A
- JRS 8.87%
- EPS Growth
- ATYR N/A
- JRS N/A
- EPS
- ATYR N/A
- JRS N/A
- Revenue
- ATYR $235,000.00
- JRS N/A
- Revenue This Year
- ATYR N/A
- JRS N/A
- Revenue Next Year
- ATYR $1,080.92
- JRS N/A
- P/E Ratio
- ATYR N/A
- JRS N/A
- Revenue Growth
- ATYR N/A
- JRS N/A
- 52 Week Low
- ATYR $1.42
- JRS $5.95
- 52 Week High
- ATYR $4.23
- JRS $8.00
- Technical
- Relative Strength Index (RSI)
- ATYR 53.70
- JRS 51.13
- Support Level
- ATYR $3.17
- JRS $8.14
- Resistance Level
- ATYR $3.83
- JRS $8.70
- Average True Range (ATR)
- ATYR 0.25
- JRS 0.18
- MACD
- ATYR -0.02
- JRS 0.05
- Stochastic Oscillator
- ATYR 43.60
- JRS 87.93
About ATYR aTyr Pharma Inc. Common Stock
aTyr Pharma Inc is a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform. The company has concentrated its research and development efforts on a newly discovered area of biology, the extracellular functionality and signaling pathways of tRNA synthetases. Its primary focus is efzofitimod, a clinical-stage product candidate which targets NRP2 to resolve chronic inflammation that can lead to fibrosis. Efzofitimod has a novel mechanism of action for potentially treating lung inflammation and fibrosis.
About JRS Nuveen Real Estate Income Fund of Beneficial Interest
Nuveen Real Estate Income Fund is a diversified closed-end investment company. The Fund invests primarily in income-producing common stocks, preferred stocks, convertible preferred stocks, and debt securities issued by real estate companies. At least 75% of the Fund's managed assets will be in securities rated investment grade.